CollPlant Biotechnologies (CLGN) Income from Continuing Operations (2017 - 2025)
CollPlant Biotechnologies (CLGN) reported Income from Continuing Operations of 3150000.0 for Q4 2025, up 20.73% on a YoY basis from 2609024.59 in Q4 2024, and up 10.18% quarter-over-quarter from 3507000.0 in Q3 2025.
CollPlant Biotechnologies (CLGN) Income from Continuing Operations (2017 - 2025) Analysis & Trends
CollPlant Biotechnologies has reported Income from Continuing Operations for 9 years, with the latest figure at 3150000.0 in Q4 2025.
- For the quarter ending Q4 2025, Income from Continuing Operations rose 20.73% year-over-year to 3150000.0; the trailing twelve-month figure through Dec 2025 stood at 1831000.0 (down 936.07% YoY), and the FY2025 full-year result was 11103000.0, up 32.76% from the prior year.
- Income from Continuing Operations for Q4 2025 stood at 3150000.0, up from 3507000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 193906000.0 in Q3 2021, with the low at 5068000.0 in Q4 2023.
- Historically, Income from Continuing Operations has averaged 9280850.0 across 5 years, with a median of 3041500.0 in 2021.
- Annual changes were most pronounced in 2021 — Income from Continuing Operations soared 698.75% — and 2022, when it slumped 102.3%.
- CollPlant Biotechnologies' Income from Continuing Operations stood at 3804000.0 in 2021, then decreased by 22.92% to 4676000.0 in 2022, then fell by 8.38% to 5068000.0 in 2023, then climbed by 21.59% to 3974000.0 in 2024, then grew by 20.73% to 3150000.0 in 2025.
- The last three Income from Continuing Operations figures came in at 3150000.0 (Q4 2025), 3507000.0 (Q3 2025), and 3178000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -56.48 Mn |
| 10 | CollPlant Biotechnologies | 7.20 Mn | 7.20 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -3.15 Mn |
| Sep 30, 2025 | -3.51 Mn |
| Jun 30, 2025 | 3.18 Mn |
| Mar 31, 2025 | 1.65 Mn |
| Dec 31, 2024 | -3.97 Mn |
| Sep 30, 2024 | -4.54 Mn |
| Jun 30, 2024 | 4.41 Mn |
| Mar 31, 2024 | 4.33 Mn |
| Dec 31, 2023 | -5.07 Mn |
| Sep 30, 2023 | -4.60 Mn |
| Jun 30, 2023 | 5.68 Mn |
| Mar 31, 2023 | 3.52 Mn |
| Dec 31, 2022 | -4.68 Mn |
| Sep 30, 2022 | -4.47 Mn |
| Jun 30, 2022 | -4.19 Mn |
| Mar 31, 2022 | 3.77 Mn |
| Dec 31, 2021 | -3.80 Mn |
| Sep 30, 2021 | 193.91 Mn |
| Jun 30, 2021 | -2.93 Mn |
| Mar 31, 2021 | 10.10 Mn |